Genitourinary Cancers

Nab-paclitaxel might offer some hope for patients with advanced urothelial cancer, an area that has lagged behind the rapid growth in available therapies for other genitourinary cancers.

As many of us are keenly aware, the coming 12 months present some very challenging times in the medical community.

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

The combination of temsirolimus plus bevacizumab was not superior to interferon plus bevacizumab as first-line therapy for patients with clear cell metastatic renal cell carcinoma.

Urologists in Cancer Care presents summaries of ongoing research relating to a variety of urologic cancers.

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.